Image: A bottle of Valeant's anti-depression drug Wellbrutin lay in disarray, much like the company's operations. Wellbrutin was one of several key drugs on which Valeant used questionable pricing strategies to increase sales, source: Wendy.
Valeant shares have been punished by the market for a combination of poor performance, a weak outlook, legal, political and financial trouble, and the warning of the potential for default.
This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!